Login to Your Account



Clinic Roundup


Thursday, February 10, 2011
R-Tech Ueno, of Tokyo, said it initiated a Phase I study of RK-023 for the treatment of hypotrichosis of the eyelashes. The company is developing the compound as a physiologically active fatty acid derivative for the treatment of dermatological diseases. The placebo-controlled, double-blind study is being conducted to evaluate safety, tolerability and pharmacokinetics of RK-023.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription